Sirolimus (rapamycin)
Email me the evidence briefEvidence
EvidenceIs sirolimus worth it? A buyer's reality checkMouse lifespan data is strong, human trials don't exist yet, and side effects are real. Here's the honest math on whether sirolimus is worth trying.Read guide →EvidenceNatural alternatives to sirolimus: what the evidence showsNo supplement matches sirolimus's mTOR inhibition in human trials. Here's what the mouse and human data on resveratrol, rapamycin foods, and fasting actually show.Read guide →EvidenceSirolimus alternatives: what the evidence actually supportsNo human lifespan trial exists for rapamycin or any alternative. Here's what NIA mouse data, acarbose, metformin, and other candidates actually show.Read guide →EvidenceSirolimus before and after: what actually changes, and whenWhat sirolimus before and after really shows: mouse lifespan data up to 60% and human case reports on skin and biomarkers, with no completed human trial yet.Read guide →EvidenceSirolimus first month: what to expect week by weekWhat actually happens in month one of off-label sirolimus: mouth ulcers around week 2, lipid shifts by week 6-8, and why no human lifespan data exists yet.Read guide →EvidenceSirolimus for beginners: the complete starter guideA plain-language guide to sirolimus for longevity: what it does, why mice live longer, what's untested in humans, and the real risks to know first.Read guide →EvidenceSirolimus pros and cons: what the evidence actually showsSirolimus extends lifespan up to 60% in mice (NIA ITP) but has zero completed human longevity trials. Here's the real risk-benefit breakdown.Read guide →EvidenceSirolimus rebound effect: what happens when you stop dosingDoes mTOR rebound when you stop sirolimus? Here's what the mouse data, pharmacokinetics, and human trial gap actually say about rebound risk.Read guide →EvidenceSirolimus results timeline: what changes and whenMouth ulcers by week 2, labs shift by week 4-8. No human lifespan trial exists yet. Here's the honest week-by-week timeline for off-label sirolimus.Read guide →EvidenceSirolimus reviews: what the human evidence actually showsSirolimus reviews sort real data from hype: strong mouse lifespan results, zero completed human longevity trials, and real risks to weigh.Read guide →EvidenceIs Sirolimus FDA approved? The honest answerSirolimus is FDA approved as an immunosuppressant, not for longevity. Here's what's approved, what's off-label, and what the human data actually shows.Read guide →EvidenceSirolimus animal studies vs human evidence: what we knowMice on rapamycin live 9-14% longer (NIA ITP data). Zero completed human lifespan trials exist. Here's the honest gap between the mouse data and the hype.Read guide →EvidenceSirolimus clinical trials: what human data actually showsNo completed human lifespan trial exists for sirolimus. Here's what PEARL, mouse ITP data, and transplant safety records actually show, with sources.Read guide →EvidenceSirolimus human studies: what the trials actually showNo completed human trial has tested rapamycin for lifespan. Here's every real human study on sirolimus and aging, what it found, and what's still missing.Read guide →EvidenceSirolimus mechanism of action: how mTOR inhibition worksSirolimus blocks mTORC1 to mimic caloric restriction in mice, extending median lifespan 9-14%. No completed human lifespan trial exists. Here's the biology.Read guide →EvidenceSirolimus rapamycin results: what the research actually showsRapamycin extends mouse lifespan 9-26% per NIA data. Human longevity trials don't exist yet. Here's the real evidence, gaps, and risks explained.Read guide →EvidenceWhat does Sirolimus actually do in the bodySirolimus (rapamycin) blocks mTOR and extends mouse lifespan up to 26%. No completed human longevity trial exists. Here's the real evidence.Read guide →